Our findings suggest that ICAM‐1 activates platelets and facilitates endothelial permeability after insufficient RFA, and anti‐platelet and anti ICAM‐1 therapy could be used to prevent HCC progression after RFA. This evidence concerns the gene ICAM1 and hepatocellular carcinoma.